SCHEMBL16355451

SCHEMBL16355451

Cc1ccc(-c2[nH]c([C@@H](C)N)nc2C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.37
MEN1 O00255 3/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CYP2C19 P33261 1/20 0.34
PARP1 P09874 1/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CA7 P43166 1/20 0.33
MAPK13 O15264 1/20 0.33
GCGR P47871 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
CDC7 O00311 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16355452 0.80 KDM4E (0.35) KDM4EMEN1ALDH1A1KMT2AMAPT
SCHEMBL38662509 0.74 KDM4E (0.43) KDM4EMEN1ALDH1A1KMT2AMAPT
SCHEMBL30603807 0.74 KDM4E (0.47) KDM4EMEN1ALDH1A1KMT2AMAPT
SCHEMBL4111920 0.71 KDM4E (0.69) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL38664277 0.71 KDM4E (0.43) KDM4EMEN1ALDH1A1KMT2AMAPT
SCHEMBL30469483 0.70 KDM4E (0.72) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL16355448 0.69 SCN10A (0.41) MEN1KMT2AMAPTLMNACYP2C19
SCHEMBL16355454 0.68 NPC1 (0.35) KDM4EALDH1A1MAPTLMNATP53
SCHEMBL24486045 0.67 KDM4E (0.49) KDM4EALDH1A1LMNATP53HPGD
SCHEMBL23758282 0.67 GAA (0.58) KDM4EMEN1ALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1L, HBS1L, HAVCR2 KDM4E 2256/4885MEN1 2896/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.